Anti-GPC3 Targeted Therapies Market
Dec 05, 2025
Evolving Landscape of Anti-GPC3 Targeted Therapies: ADCs, CAR-T Cells, and Beyond
Glypican-3 (GPC3) has emerged as one of the most promising therapeutic targets in oncology, particularly in hepatocellular carcinoma and select solid tumors. As a cell surface heparan sulfate proteoglycan that is overexpressed in approximately 75% of hepatocellular carcinoma cases while remaining virtually absent i...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
